The Path to Least Resistance: The Emerging Role of Noncovalent BTK Inhibitors in CLL/SLL Across Clinical Practice Settings
Program DescriptionThe advent of covalent Bruton’s tyrosine kinase inhibitors (cBTKi) (e.g., ibrutinib) in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has significantly enhanced long-term outcomes and quality-of-life for patients as the treatment landscape continu
Category
Format
Credits
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
Cost $0.00
The ARIA Toolkit: An Interdisciplinary Curriculum to Optimize Team-Based Management of Amyloid-Related Imaging Abnormalities in Alzheimer’s Disease
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD platform.Program DescriptionThe introduction of disease modifying amyloid targeting therapies for Alzheim
Category
Format
Credits
Cost $0.00
Alzheimer’s Disease Diagnosis Time Outs: A Deep Dive into Challenging Clinical Scenarios for Early Alzheimer's Diagnosis and Treatment
Program DescriptionThe management of AD is at the beginning of a seismic paradigm shift. Historically, clinical strategy has been tailored to a therapeutic armamentarium that was nonspecific and directed solely at symptom management.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Cost $0.00

Pages